Hui-Ming Chang

Hui-Ming Chang is a Professor in the Department of Pharmacology and Toxicology at the University of Arkansas for Medical Sciences (UAMS) College of Medicine, with a joint appointment in Internal Medicine. He previously held academic roles at Harvard Medical School, the University of Texas Health Science Center at Houston, and the University of Missouri. His clinical and research expertise spans cardio-oncology, cancer therapy-induced cardiotoxicity, and pain management.

Education:

• MD: National Taiwan University
• MPH and MS: Harvard T.H. Chan School of Public Health
• Clinical Training: George Washington University, Boston University, and Harvard Medical School/Boston Children’s Hospital

Research Interests: Focuses on preventing anthracycline-induced cardiotoxicity via early dexrazoxane administration (NIH-funded), SUMOylation pathways, and opioid mechanisms in pain. His lab elucidated the role of Topoisomerase 2 isoforms in doxorubicin’s dual effects on tumors vs. cardiomyocytes. He co-discovered Sentrin/SUMO, a critical post-translational modifier.

Grants/Awards: Principal Investigator of NIH R01 HL151993 (2020–2025). Served on national pain management guidelines committees, including the American Society of Anesthesiologists (ASA). Member of scientific advisory boards at MD Anderson Cancer Center and University of Texas clinical research centers.

Publications: Over 30 peer-reviewed articles since 1996, including seminal work on SUMO biology, cardio-oncology trials, and pain mechanisms. His 2020 Physiological Reviews paper on SUMO highlights translational research impact.

Labs/Teams: Active in UAMS’ cardio-oncology translational research programs. Collaborates with multidisciplinary teams on clinical trials, sepsis immunology, and cancer pain management strategies. Former director of the American Academy of Pain Medicine’s education initiatives.